Leaders from the UConn John Dempsey Hospital Quality Department explain the importance of quality management in a hospital setting and what their team.
Reportable, Inc.: Health Canada Clears Pacylex Pharmaceuticals for New Phase 1 Clinical Trial to Evaluate PCLX-001 Capsules in the Treatment of Hematologic and Solid Tumor Cancers
Key Takeaways:
Scientists at the University of Alberta have recently published evidence that a new drug could work in blood cancers by targeting B-cell signaling.
Scientists at the University of Alberta also published a study showing potential in breast cancer.
PCLX-001 led to significant tumor regression in mouse models, including completely eliminating lymphoma tumors derived from a patient whose cancer had stopped responding to the standard therapies CHOP and Roche s Rituxan.
Click image above to view full announcement.
Clover Health
Last year, Clover Health touted big plans to grow membership through an untested government program.
It said it already had 200,000 new members under contract in that program.
Wall Street analysts are now raising questions about Clover s projections.
Investors are souring on a hot healthcare stock that billionaire investor Chamath Palihapitiya recently helped take public.
Clover Health, an insurer that provides private health plans for the elderly, has seen its stock decline by almost half since it completed a $3.7 billion deal with one of Palihapitiya s SPACs in January and began trading.
While some of the tumble can be chalked up to frothy trading, industry analysts are raising fresh questions about ambitious growth plans the company laid out in its pitch to investors before going public.
(1)
STOCKHOLM, March 10, 2021 /PRNewswire/
Cantargia AB today announced the submission of a clinical trial application investigating antibody CAN04 in combination with FOLFIRINOX for first line treatment of metastatic pancreatic cancer (PDAC). The trial is designed to complement the ongoing clinical program and subsequently broaden the development of CAN04. The phase Ib trial is planned to be performed in up to 30 patients in France and Spain. The current estimate is to start therapy in the first patient in the end of Q2 2021.
Cantargia develops antibody-based pharmaceuticals against interleukin-1 receptor accessory protein (IL1RAP). The antibody CAN04 binds IL1RAP with high affinity and functions through both blockade of IL-1 signaling and Antibody-Dependent Cellular Cytotoxicity (ADCC). Preclinical data show that CAN04 can increase the efficacy of chemotherapy. CAN04 is investigated in an open label phase I/IIa clinical trial, CANFOUR, examining combination with two different
(1)
STOCKHOLM, SWEDEN - March 10, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Modus Therapeutics is preparing a clinical development program of its drug candidate sevuparin in patients suffering from sepsis/septic shock, and possibly also other severe inflammatory conditions arising in conjunction with major trauma, surgery, autoimmunity and viral infections. Modus Therapeutics expects to start the first clinical trial in this new indication around the end of 2021. Sevuparin has already demonstrated a favorable safety profile in clinical trials for other indications.
Patients suffering from sepsis are at risk of developing septic shock and multi-organ failure. Septic shock is a leading cause of death in intensive care units, with mortality rates typically exceeding 30 percent. There is currently no specific pharmaceutical treatment available for the treatment of sepsis. As a result, it is one of the costliest conditions to tre